The clinical effectiveness and safety of imiquimod versus podophyllotoxin in the topical treatment of condylomata acuminata: a systematic review and meta-analysis Authors: Musab Maqsood, Ali Ahmad Nadeem, Abdullah Shahid, Muhammad Khan Buhadur Ali, Mohammad Faaiz, Muhammad Zain Raza, Hafiz Muhammad Ehsan Arshad, Fajar Noor, Muhammad Omais, Muhammad Zeshan Asif, Muhammad Farhan Zafar Baloch, Javeria Mahmood, Nida Idrees, Oshaz Fatima, Rejina Chhetri Published: 2026 ABSTRACT Background:Imiquimod (IMQ) and podophyllotoxin (PDX) are two of the most common self-applied topical therapies for condyloma acuminatum. This review aims to directly compare their clinical effectiveness and safety profiles.Materials and methods:Records from two databases and two trial registers were screened for eligibility. The Mantel-Haenszel method was used for statistical analysis, using a fixed- or random-effects model depending on the calculated heterogeneity.Results:Five studies, two RCTs and three cohorts, were included. There was no statistically significant difference in the clinical effectiveness (RR = 0.98; 95% CI: 0.85–1.13; P = 0.74) and adverse effects (RR = 1.06; 95% CI: 0.73–1.53; P = 0.78) between IMQ and PDX. Subgroup analysis revealed a higher frequency of adverse effects with IMQ compared to PDX in adults (RR = 1.22; 95% CI: 1.03–1.46; P = 0.02) and a lower frequency in children (RR = 0.51; 95% CI: 0.27–0.99; P = 0.05), with a statistically significant difference between these two subgroups (P = 0.01). The reviewed studies suggested that the time to complete clearance was comparable, wart recurrence was higher, and the time to recurrence was shorter in IMQ compared to PDX. IMQ may be slower in achieving complete clearance but better in preventing wart recurrence in vaccinated individuals.Conclusions:IMQ has comparable clinical effectiveness, more frequent adverse effects in adults, and less frequent adverse effects in children compared to PDX. Additionally, IMQ’s lower wart recurrence may suggest a potential benefit in vaccinated individuals. Thus, IMQ may be slightly better than PDX in these populations, which warrants further research. Nevertheless, the utilized studies had small sample sizes and inadequate power to draw reasonable conclusions (low certainty). Introduction Condylomata acuminata (CA) (singular: condyloma acuminatum), also known as an anogenital wart, are a sexually transmitted disease (STD) caused by the human papillomavirus (HPV), mainly HPV 6 and 11[1]. They cause tan or flesh-colored, cauliflower-like, verrucous growths that are not premalignant[2–4]. They may occur on the penis, vulva, anus, and other structures in the anogenital region[5,6]. These warts can not only cause physical discomfort, itching, obstruction, and, rarely, pain[5], but are also associated with anxiety, depression, or reduced social functioning[7].HIGHLIGHTSImiquimod (IMQ) and podophyllotoxin (PDX) show comparable clinical effectiveness.IMQ causes more adverse effects in adults but fewer in children compared to PDX.Time to complete clearance is similar, but recurrence is lower with IMQ in vaccinated patients.IMQ’s immunological mechanism may confer long-term benefits in human papillomavirus–vaccinated populations.Findings support IMQ as a slightly preferable option in children and vaccinated individuals. HIGHLIGHTS Imiquimod (IMQ) and podophyllotoxin (PDX) show comparable clinical effectiveness. Imiquimod (IMQ) and podophyllotoxin (PDX) show comparable clinical effectiveness. IMQ causes more adverse effects in adults but fewer in children compared to PDX. IMQ causes more adverse effects in adults but fewer in children compared to PDX. Time to complete clearance is similar, but recurrence is lower with IMQ in vaccinated patients. Time to complete clearance is similar, but recurrence is lower with IMQ in vaccinated patients. IMQ’s immunological mechanism may confer long-term benefits in human papillomavirus–vaccinated populations. IMQ’s immunological mechanism may confer long-term benefits in human papillomavirus–vaccinated populations. Findings support IMQ as a slightly preferable option in children and vaccinated individuals. Findings support IMQ as a slightly preferable option in children and vaccinated individuals. This condition has a significant worldwide burden, with an estimated prevalence of 0.13–5.1% in the adult population, most of whom are aged between 25 and 29 years[8]. The burden of HPV-related diseases varies by region, being lower in areas with widespread HPV vaccination, such as Australia[9] and some European countries[10], and higher in areas with less vaccination and fewer resources, such as Sub-Saharan Africa[11]. Furthermore, the burden also depends on sexual habits and the accessibility of prompt healthcare in each region. The ideal approach to treating conditions like CA is to target the underlying cause, which is HPV. However, developing direct antiviral therapies against HPV is challenging because the viral proteins that can be targeted for treatment vary significantly across different serotypes, necessitating separate therapies for each type[12]. Additionally, since HPV relies on host DNA polymerase and other cellular machinery, targeting these host proteins could cause significant harm to the host[13]. Currently, available therapies for CA focus on removing the wart tissue rather than eradicating the virus[10,12]. These therapies include both clinic-based options, such as excision, cryotherapy, cautery, and laser, and self-applied options, such as podophyllin, podophyllotoxin (PDX), imiquimod (IMQ), and catechins[10,14–16]. This approach presents problems for clinical decision-making because these therapies have overlapping spectra of efficacy and safety, leading to patients not always receiving the best-suited treatment option[10]. As a result, incomplete eradication or recurrence of these warts is common. This review aims to address these issues for two of the most commonly prescribed patient-applied topical therapies: PDX and IMQ[17]. PDX is a purified and standardized active ingredient of podophyllin, a mixture of resins sourced from certain Podophyllum species, especially P. peltatum and P. hexandrum[18,19]. PDX targets tubulin and DNA topoisomerase and inhibits mitosis in neoplastic cells in the warts[20]. On the other hand, IMQ binds to cell surface receptors, such as Toll-like receptors, induces the release of cytokines, and modifies the body’s immune response, enabling it to better clear the virus, i.e., HPV[21]. Although both these therapies are effective, they differ in dosing regimen and the nature of adverse effects. The standard course for IMQ (5% cream) is three times weekly for approximately 16 weeks, while PDX (0.5% solution or 0.15% cream) is applied twice daily for 3 days, followed by 4 rest days, for up to 4 weeks[10]. IMQ may cause itching, soreness, flaking, and erosion locally and, in rare cases, headache, myalgia, and flu-like symptoms systemically[22]. On the other hand, PDX may cause erythema and erosions locally and hepatic dysfunction, psychiatric symptoms, hair loss, and bone marrow suppression systemically[15,19]. Ultimately, the choice between these treatments depends on the preference of the physician and the country they practice in, since IMQ is not available in some countries. Despite the comparable use of these drugs, there is a scarcity of studies and meta-analyses that directly compare them, with most of them comparing one of the two with a placebo or some third drug. Furthermore, individual direct-comparison studies with small sample sizes fail to establish a conclusive result. This review aims to fill this gap by conducting a head-to-head comparative analysis of IMQ and PDX to ascertain whether they differ in terms of clinical effectiveness, adverse effects, and recurrence, thereby informing clinical decisions. This review also adheres to the TITAN Guidelines 2025, which outline the best practices for transparency in the use of AI in research reporting[23]. Methodology This review adheres to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews) guidelines to ensure methodological rigor and transparency. The protocol for this review was registered on PROSPERO before the start of the review (Registration ID: CRD42024550270). Study outcomes There were two primary outcomes, which were pooled in a meta-analysis: clinical effectiveness and adverse effects. Clinical effectiveness was represented by the complete clearance rate, i.e., the number of people who had all their warts cleared at any time during the course of the treatment divided by all the people who received the treatment. Adverse effects were represented by the adverse event rate, i.e., the number of people who had one or more adverse events at any time during the course of the treatment divided by all the people who received the treatment. There were four secondary outcomes, which were compiled in a systematic review: time to complete clearance, wart recurrence, time to wart recurrence, and other measures of response to treatment. Time to complete clearance was the time interval from the start of the treatment until the complete clearance of warts. Wart recurrence was represented by the wart recurrence rate, i.e., the number of people who had a recurrence of warts at any point after complete clearance divided by the total number of people who had complete clearance of warts. Time to wart recurrence was the time interval from complete wart clearance until the recurrence of warts at any point. Other measures included any other ways of reporting the clearance of warts. Search strategy The following PICO criteria were used to search for potential studies: (P) Patients with CA, (I) Imiquimod, (C) Podophyllotoxin, and (O) Clinical effectiveness, adverse effects, and recurrence. A comprehensive literature search, using both controlled vocabulary and corresponding text words, was conducted in June 2024 using two electronic databases (PubMed and Cochrane CENTRAL) and two trial registers (ClinicalTrials.gov and WHO ICTRP). There were no language or publication date restrictions. Additional studies were found by searching through the references of included studies (ancestry approach) and the studies citing the included studies (descendancy approach). Common search engines (such as Google and Bing) were also used to look through gray literature. The search strategies have been provided in Supplemental Digital Content Table 1, available at: http://links.lww.com/MS9/B260. Eligibility criteria The studies were deemed eligible if all of the following inclusion criteria were met: (1) human studies; (2) controlled trials and cohorts (both prospective and retrospective); (3) studies with CA patients of any age or stage; and (4) studies with patients receiving PDX and IMQ for any specified period of time. The studies were deemed ineligible if they met at least one of the following exclusion criteria: (1) studies with patients only receiving combination therapy regimens of PDX and IMQ; (2) studies not reporting any of the outcomes or number of participants separately for both PDX and IMQ groups; (3) in vitro studies or only laboratory research; (4) ongoing trials without any reported outcomes or meeting abstracts without available data for analysis; and (5) studies not reporting any of the outcomes of interest for this review. If a study had only some of the participants fulfilling the exclusion criteria, separate data were collected for the rest of the participants. Study selection and data extraction First, two authors independently screened the titles and abstracts of all the studies obtained from the search, based on the inclusion criteria. Second, the full texts of the selected studies were independently screened, based on the exclusion criteria. All conflicts between authors were resolved by mutual consensus. Third, the studies obtained through ancestry and descendancy approaches were similarly screened. Finally, two authors independently used a standardized form to extract data from each included study, and the two forms were cross-checked, and a consensus was reached. The extracted information covered study characteristics (author name, year, setting and country, design, and duration), participant details (including age, sex, and treatment plan), and outcomes (primary and secondary). Risk of bias and quality assessment The risk of bias was assessed using the Newcastle-Ottawa Scale (NOS)[24] and ROB 2.0[25]. The NOS is a tool for evaluating the quality of non-randomized studies, such as case–control and cohort studies. It assesses three aspects: selection of study groups, comparability of study groups, and assessment of either the exposure or outcome. Each study can receive up to nine stars. ROB 2.0, from the Cochrane Collaboration, assesses the risk of bias in randomized controlled trials (RCTs) across five domains: the randomization process, deviations from intended interventions, missing outcome data, outcome measurement, and selection of the reported result. The quality of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) tool26. Statistical analysis, sensitivity analysis, and assessment of publication bias All statistical analyses were conducted using RevMan Web. The Mantel-Haenszel (M-H) method was used to analyze dichotomous outcomes, with heterogeneity calculated using the Cochrane Q and I2 tests. If heterogeneity was significant (P < 0.1 or I2 > 50%), a random-effects model was used; otherwise, a fixed-effects model was applied. Pooled risk ratios (RRs) and 95% confidence intervals (95% CIs) were used to compare the two groups. Subgroup analysis was performed based on (1) age, i.e., adults (> 18 years) and children (< 18 years) for both primary outcomes, and (2) formulation of PDX, i.e., 0.5% gel/solution and 0.15% cream for clinical effectiveness only. Sensitivity analysis was conducted by sequentially removing individual studies and observing the subsequent changes in the analysis results. Funnel plots were constructed using RevMan Web and were utilized to assess publication bias. Results Characteristics and risk of bias assessment The initial search yielded a total of 925 records. After the removal of 85 duplicates, 840 records underwent title-and-abstract screening, and a further 829 were excluded. Following the full-text screening of the remaining 11 records, five were found eligible. Furthermore, no additional records were deemed eligible among the 540 obtained via ancestry and descendancy approaches. While reviewing gray literature using common search engines, no additional unique studies were identified. The PRISMA flowchart for this process is provided in Figure 1.Figure 1.PRISMA flowchart for study selection. PRISMA flowchart for study selection. The five included studies consisted of two RCTs[27,28] and three retrospective cohorts[29–31], published between 2001 and 2021. The characteristics of these studies are given in Table 1. The risk of bias for the cohorts is provided in Supplemental Digital Content Table 2, available at: http://links.lww.com/MS9/B260. All of them had a low risk of bias. The risk of bias for the individual outcomes of the RCTs is provided in Supplemental Digital Content Table 3, available at: http://links.lww.com/MS9/B260. Only one outcome, i.e., adverse effects, of Komericki et al[28] received a “some concerns” rating, while all other outcomes of both studies had a low risk of bias.Table 1Characteristics of the included studies.StudyStudy designParticipantsEligibility criteriaTherapy regimenDuration of treatmentReported outcomesTotalIMQPDXIMQPDXIMQPDXMoresi et al[31]Cohort25817Diagnosis of CA5% cream three times each week0.5% gel single weekly application, increasing by one application a week to a maximum of twice a day for 3 consecutive days followed by a 4-day break before repeating the cycle2–4 months1 week to 4 monthsClinical effectiveness and adverse effectsKomericki et al[28]RCT512526Inclusion: Presence of never treated CA5% cream used 3 times per week0.5% solution used 2 times on 3 consecutive days per weekUntil the warts completely cleared, or for a maximum period of 16 weeksUntil the warts completely cleared, or for a maximum period of 4 weeksClinical effectiveness and adverse effectsExclusion: Age below 18 years, lack of informed consent, known immunosuppression, pregnancy, breastfeeding, involvement of the anal canal, or severe disease requiring surgeryStefanaki et al[29]Cohort381020Patients < 12 years old with CA5% cram given 3 times/week at night for 6–10 hoursCream or solution twice daily for 3 consecutive days giving a 4-day restN/AN/AOther measures of clinical effectiveness (response to treatment)Gilson et al[27]RCT506126127Inclusion: Adults, aged ≥ 18 years, presenting to participating clinics with external CA that, in the opinion of the investigator, could be appropriately treated with either self-administered IMIQ cream or self-administered PDX cream. Patients with a first episode of warts, and patients for whom this was a repeat episode, were eligible provided that they had not received treatment for warts in the previous 3 months.5% cream for up to 16 weeks0.15% cream for 4 weeks, which was extended to up to 16 weeks if warts persisted48 weeks, with scheduled visits at weeks 4, 8, 16, 24, and 4848 weeks, with scheduled visits at weeks 4, 8, 16, 24, and 48Clinical effectiveness, adverse effects, time to complete clearance, wart recurrence, and time to wart recurrenceExclusion: Previously had qHPV vaccine (but having had bivalent HPV vaccine was not an exclusion criterion), patients with any contraindication to any of the products.Those with a total wart area of > 4 cm2, and patients requiring topical steroids applied to the affected area, or on systemic immunosuppressive agents.Nicolaidou et al[30]Cohort347202145Inclusion: Otherwise healthy males and females age 18 years and older with a clinically diagnosed first episode of CA lasting no more than 3 months and monotherapy with either an 8-week course of imiquimod 5% cream or a 4-week course of podophyllotoxin5% cream 3 times weekly0.5% solution on “keratinized” and 0.15% cream on “partially keratinized” sites each week twice daily for 3 consecutive days, followed by 4 days of rest8 weeks4 weeksClinical effectiveness and other measures (> 50% reduction in wart area)Exclusion: Receiving any treatment for CA before presentation to our department, presence of either intra-anal/intravaginal warts or warts of the urethral meatus, presence of giant condylomata (Buschke–Lowenstein tumors), presence of only one wart or wart area larger than 6 cm2, and pregnancy Table 2Summary of secondary outcomes.Serial no.Secondary outcomeStudyResultsMeasureImiquimodPodophyllotoxin1Time to complete clearanceGilson et al[27]Median (days)14417795% CI (days)91–13877–144N82792Wart recurrenceGilson et al[27]n2621N8279Percentage (%)31.726.63Time to wart clearanceGilson et al[27]20th Percentile (days)12215095% CI (days)56–17976–273N26214Other measures of clinical effectivenessStefanaki et al[29] (response to treatment)n616N1020Percentage (%)60.080.0Nicolaidou et al[30] (> 50% reduction in wart area)n142111N202145Percentage (%)70.376.6p0.19695% CI denotes 95% confidence interval; n denotes the number of events observed; and N denotes the total number of participants. Table 1Characteristics of the included studies.StudyStudy designParticipantsEligibility criteriaTherapy regimenDuration of treatmentReported outcomesTotalIMQPDXIMQPDXIMQPDXMoresi et al[31]Cohort25817Diagnosis of CA5% cream three times each week0.5% gel single weekly application, increasing by one application a week to a maximum of twice a day for 3 consecutive days followed by a 4-day break before repeating the cycle2–4 months1 week to 4 monthsClinical effectiveness and adverse effectsKomericki et al[28]RCT512526Inclusion: Presence of never treated CA5% cream used 3 times per week0.5% solution used 2 times on 3 consecutive days per weekUntil the warts completely cleared, or for a maximum period of 16 weeksUntil the warts completely cleared, or for a maximum period of 4 weeksClinical effectiveness and adverse effectsExclusion: Age below 18 years, lack of informed consent, known immunosuppression, pregnancy, breastfeeding, involvement of the anal canal, or severe disease requiring surgeryStefanaki et al[29]Cohort381020Patients < 12 years old with CA5% cram given 3 times/week at night for 6–10 hoursCream or solution twice daily for 3 consecutive days giving a 4-day restN/AN/AOther measures of clinical effectiveness (response to treatment)Gilson et al[27]RCT506126127Inclusion: Adults, aged ≥ 18 years, presenting to participating clinics with external CA that, in the opinion of the investigator, could be appropriately treated with either self-administered IMIQ cream or self-administered PDX cream. Patients with a first episode of warts, and patients for whom this was a repeat episode, were eligible provided that they had not received treatment for warts in the previous 3 months.5% cream for up to 16 weeks0.15% cream for 4 weeks, which was extended to up to 16 weeks if warts persisted48 weeks, with scheduled visits at weeks 4, 8, 16, 24, and 4848 weeks, with scheduled visits at weeks 4, 8, 16, 24, and 48Clinical effectiveness, adverse effects, time to complete clearance, wart recurrence, and time to wart recurrenceExclusion: Previously had qHPV vaccine (but having had bivalent HPV vaccine was not an exclusion criterion), patients with any contraindication to any of the products.Those with a total wart area of > 4 cm2, and patients requiring topical steroids applied to the affected area, or on systemic immunosuppressive agents.Nicolaidou et al[30]Cohort347202145Inclusion: Otherwise healthy males and females age 18 years and older with a clinically diagnosed first episode of CA lasting no more than 3 months and monotherapy with either an 8-week course of imiquimod 5% cream or a 4-week course of podophyllotoxin5% cream 3 times weekly0.5% solution on “keratinized” and 0.15% cream on “partially keratinized” sites each week twice daily for 3 consecutive days, followed by 4 days of rest8 weeks4 weeksClinical effectiveness and other measures (> 50% reduction in wart area)Exclusion: Receiving any treatment for CA before presentation to our department, presence of either intra-anal/intravaginal warts or warts of the urethral meatus, presence of giant condylomata (Buschke–Lowenstein tumors), presence of only one wart or wart area larger than 6 cm2, and pregnancy Characteristics of the included studies. Table 2Summary of secondary outcomes.Serial no.Secondary outcomeStudyResultsMeasureImiquimodPodophyllotoxin1Time to complete clearanceGilson et al[27]Median (days)14417795% CI (days)91–13877–144N82792Wart recurrenceGilson et al[27]n2621N8279Percentage (%)31.726.63Time to wart clearanceGilson et al[27]20th Percentile (days)12215095% CI (days)56–17976–273N26214Other measures of clinical effectivenessStefanaki et al[29] (response to treatment)n616N1020Percentage (%)60.080.0Nicolaidou et al[30] (> 50% reduction in wart area)n142111N202145Percentage (%)70.376.6p0.19695% CI denotes 95% confidence interval; n denotes the number of events observed; and N denotes the total number of participants. Summary of secondary outcomes. 95% CI denotes 95% confidence interval; n denotes the number of events observed; and N denotes the total number of participants. Primary outcomes Clinical effectiveness In the analysis based on the age of the patient, summary data statistics from four studies consisting of a total of 339 IMQ and 303 PDX therapies were included in the analysis using the M-H statistical method shown in Figure 2. A fixed-effects model was used due to low heterogeneity (I2 = 27%). The pooled RR was 0.98 (95% CI: 0.85–1.13) with no statistically significant difference (P = 0.74) between the IMQ and PDX groups. For the subgroup of adults, the summary data statistics from three studies consisting of a total of 331 IMQ and 286 PDX therapies were included. The pooled RR was 0.98 (95% CI: 0.85–1.14) with no statistically significant difference (P = 0.84) between the two therapy groups. For the subgroup of children, the summary data statistics from one study consisting of a total of 8 IMQ and 17 PDX therapies were included. The pooled RR was 0.85 (95% CI: 0.55–1.31) with no statistically significant difference (P = 0.47) between the IMQ and PDX groups. The test for subgroup differences was also not statistically significant (P = 0.53).Figure 2.Data analysis for clinical effectiveness (based on the age of patient) using RevMan Web. Data analysis for clinical effectiveness (based on the age of patient) using RevMan Web. In the analysis based on the formulation of PDX, summary data statistics from four studies consisting of a total of 305 IMQ and 285 PDX therapies were included in the analysis using the M-H statistical method shown in Figure 3. A random-effects model was used due to high heterogeneity (I2 = 74%). The pooled RR was 0.86 (95% CI: 0.62–1.20) with no statistically significant difference (P = 0.37) between the IMQ and PDX groups. For the subgroup of 0.5% PDX gel/solution, the summary data statistics from three studies consisting of a total of 120 IMQ and 146 PDX therapies were included. The pooled RR was 0.66 (95% CI: 0.30–1.44) with no statistically significant difference (P = 0.30) between the two therapy groups. For the subgroup of 0.15% PDX cream, the summary data statistics from two studies consisting of a total of 185 IMQ and 130 PDX therapies were included. The pooled RR was 1.09 (95% CI: 1.93–1.27) with no statistically significant difference (P = 0.29) between the IMQ and PDX groups. The test for subgroup differences was also not statistically significant (P = 0.22).Figure 3.Data analysis for clinical effectiveness (based on the PDX formulation) using RevMan Web. Data analysis for clinical effectiveness (based on the PDX formulation) using RevMan Web. Adverse effects The summary data statistics from three studies, consisting of a total of 154 IMQ and 168 PDX therapies, were included in the analysis using the M-H statistical method shown in Figure 4. A random-effects model was used due to high heterogeneity (I2 = 71%). The pooled RR was 1.06 (95% CI: 0.73–1.53), with no statistically significant difference (P = 0.78) between the IMQ and PDX groups. For the subgroup of adults, the summary data statistics from two studies, consisting of a total of 146 IMQ and 151 PDX therapies, were included. The pooled RR was 1.22 (95% CI: 1.03–1.48), with a statistically significant difference (P = 0.02) between the two therapy groups, i.e., the risk of developing one or more adverse events in the IMQ group is 1.22 times that in the PDX group. For the subgroup of children, the summary data statistics from one study, consisting of a total of eight IMQ and 17 PDX therapies, were included. The pooled RR was 0.51 (95% CI: 0.27–0.99), with a statistically significant difference (P = 0.05) between the two therapy groups, i.e., the risk of developing one or more adverse events in the IMQ group is 0.51 times that in the PDX group. The test for subgroup differences was also significant (P = 0.01).Figure 4.Data analysis for adverse effects using RevMan Web. Data analysis for adverse effects using RevMan Web. Secondary outcomes The results are summarized in Table 2. Time to complete clearance Only one study[27] reported this outcome. The study reported the summary data for 82 participants in the IMQ group and 79 in the PDX group. It showed that the time to complete clearance was comparable, i.e., a median of 114 days (95% CI = 91–138 days) for IMQ and 117 days (95% CI = 77–144 days) for PDX. Wart recurrence Only one study[27] reported this outcome. The study reported the summary data for 82 participants in the IMQ group and 79 in the PDX group. It showed that warts recurred in 26 out of 82 people (31.7%) in the IMQ group and 21 out of 79 people (26.6%) in the PDX group, i.e., it was higher for IMQ. Time to wart recurrence Only one study[27] reported this outcome. The study provided summary data for 26 participants in the IMQ group and 21 in the PDX group. It reported a 20th percentile of 122 days (95% CI = 56–179 days) for IMQ and 150 days (95% CI = 76–273 days) for PDX, i.e., it was longer for PDX. Other measures of clinical effectiveness Two studies[29,30] reported measures of clinical effectiveness other than complete clearance. Stefanaki[29] reported a “response to treatment” in six out of 10 children taking IMQ and in 16 out of 20 children taking PDX. Nicolaidou[30] reported a “> 50% reduction in wart area” in 142 out of 202 people (70.3%) in the IMQ group and in 111 out of 145 people (76.6%) in the PDX group, with no statistically significant difference between the two (P = 0.196). However, when the patients were stratified on the basis of the site of warts, the PDX group (76.0%) had a statistically significant (P = 0.001) higher > 50% reduction in wart area than the IMQ group (54.3%) on keratinized sites. Sensitivity analysis, publication bias, and grading of outcomes The results of the sensitivity analysis are given in Supplemental Digital Content Table 4, available at: http://links.lww.com/MS9/B260. The clinical effectiveness analyses reported similar results even when individual studies were removed from the analysis. The analyses of adverse effects became statistically insignificant in the subgroup of adults when either of the studies was removed. Since the number of studies for both outcomes fell below the recommended 10, ascertainment of publication bias was not possible. Nevertheless, the funnel plots for clinical effectiveness and adverse effects are given in Supplemental Digital Content Figure 1, available at: http://links.lww.com/MS9/B259, and Supplemental Digital Content Figure 2, available at: http://links.lww.com/MS9/B259, respectively. The quality of evidence for each outcome was assessed in each subgroup and overall. The quality was high for adverse effects in adults, low for adverse effects in children, and very low for the rest. The results of the GRADE assessment are provided in Table 3.Table 3GRADE assessment of the quality of evidence for each primary outcome.Imiquimod compared to podophyllotoxin for condylomata acuminataPatient or population: Patients with condylomata acuminataSetting: OutpatientIntervention: ImiquimodComparison: PodophyllotoxinOutcomesNo. of participants (studies) Follow-upCertainty of the evidence (GRADE)Relative effect (95% CI)Anticipated absolute effectsRisk with podophyllotoxinRisk difference with imiquimodClinical effectiveness – adults617 (3 non-randomized studies)⨁◯◯◯RR 0.98 (0.85–1.14)500 per 100010 fewer per 1000 (75 fewer to 70 more)Very low a, bClinical effectiveness – children25 (1 non-randomized study)⨁◯◯◯RR 0.85 (0.55–1.31)882 per 1000132 fewer per 1000 (397 fewer to 274 more)Very low bClinical effectiveness – total642 (4 non-randomized studies)⨁◯◯◯RR 0.98 (0.85–1.13)521 per 100010 fewer per 1000 (78 fewer to 68 more)Very low a,bAdverse effects – adults297 (2 RCTs)⨁⨁⨁⨁RR 1.22 (1.03–1.46)397 per 100087 more per 1000 (12 more to 183 more)High cAdverse effects –children25 (1 non-randomized study)⨁⨁◯◯RR 0.61 (0.27–0.99)1000 per 1000390 fewer per 1000 (730 fewer to 10 fewer)Low cAdverse effects –total322 (3 non-randomized studies)⨁◯◯◯RR 1.06 (0.73–1.53)458 per 100028 more per 1000 (124 fewer to 243 more)Very low a,bThe risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).CI, confidence interval; RR, risk ratioGRADE Working Group grades of evidenceHigh certainty: we are very confident that the true effect lies close to that of the estimate of the effect.Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.aHeterogeneity > 66%.b95% CIs cross the line of no effect.c95% CI very close to the line of no effect. Table 3GRADE assessment of the quality of evidence for each primary outcome.Imiquimod compared to podophyllotoxin for condylomata acuminataPatient or population: Patients with condylomata acuminataSetting: OutpatientIntervention: ImiquimodComparison: PodophyllotoxinOutcomesNo. of participants (studies) Follow-upCertainty of the evidence (GRADE)Relative effect (95% CI)Anticipated absolute effectsRisk with podophyllotoxinRisk difference with imiquimodClinical effectiveness – adults617 (3 non-randomized studies)⨁◯◯◯RR 0.98 (0.85–1.14)500 per 100010 fewer per 1000 (75 fewer to 70 more)Very low a, bClinical effectiveness – children25 (1 non-randomized study)⨁◯◯◯RR 0.85 (0.55–1.31)882 per 1000132 fewer per 1000 (397 fewer to 274 more)Very low bClinical effectiveness – total642 (4 non-randomized studies)⨁◯◯◯RR 0.98 (0.85–1.13)521 per 100010 fewer per 1000 (78 fewer to 68 more)Very low a,bAdverse effects – adults297 (2 RCTs)⨁⨁⨁⨁RR 1.22 (1.03–1.46)397 per 100087 more per 1000 (12 more to 183 more)High cAdverse effects –children25 (1 non-randomized study)⨁⨁◯◯RR 0.61 (0.27–0.99)1000 per 1000390 fewer per 1000 (730 fewer to 10 fewer)Low cAdverse effects –total322 (3 non-randomized studies)⨁◯◯◯RR 1.06 (0.73–1.53)458 per 100028 more per 1000 (124 fewer to 243 more)Very low a,bThe risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).CI, confidence interval; RR, risk ratioGRADE Working Group grades of evidenceHigh certainty: we are very confident that the true effect lies close to that of the estimate of the effect.Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.aHeterogeneity > 66%.b95% CIs cross the line of no effect.c95% CI very close to the line of no effect. GRADE assessment of the quality of evidence for each primary outcome. Heterogeneity > 66%. 95% CIs cross the line of no effect. 95% CI very close to the line of no effect. Discussion Although current research still supports physician-applied ablative therapies, such as cryotherapy, electrosurgery, and laser surgery, as being superior to topical treatments[10,17,32], focusing research on topical therapies is crucial given the common preference of patients for them. The general consensus regarding these therapies is that there is no significant difference in their effectiveness in achieving complete clearance by the end of the treatment duration[10,33]. Our results support this notion, as no significant difference in clearance rates was found between IMQ and PDX (45.4% vs. 52.1%; RR = 0.98, 95% CI: 0.85–1.13, P = 0.74). However, it is important to consider the treatment duration used in these studies when interpreting these results. The standard course for IMQ (16 weeks) is longer than PDX (up to 4 weeks)[10]. This regimen was followed by two of the included studies[28,31], while the other two modified the regimen, with Nicolaidou[30] using a shorter 8-week course for IMQ and Gilson et al[27] using a 16-week therapy for both PDX and IMQ. The importance of treatment duration is evident in the RCT by Gilson et al[27], in which PDX showed slightly better efficacy for complete clearance than IMQ (61.3% vs. 55%) when used for 16 weeks[27]. However, when comparing the number of patients achieving complete clearance at the end of the standard treatment course for PDX with those of the standard treatment course for IMQ, PDX was found to be less effective (18% vs. 49.2%). This provides insights into setting up the optimum duration of therapy for patients, as longer treatment durations can achieve complete clearance. Some previous network meta-analyses (NMAs) found that PDX 0.5% solution (not the 0.15% cream formulation) was significantly more effective than IMQ 5% cream for complete clearance of warts[17,34]. To test this, we performed a subgroup analysis that separated data according to the type of PDX used. It showed no significant difference when comparing the PDX 0.5% formulation with IMQ, as indicated by an RR of 0.66 (95% CI: 0.30–1.44; P = 0.30). Furthermore, the test for group differences was also non-significant (X2 = 1.49; P = 0.22), suggesting that the 0.5% solution did not demonstrate superior efficacy over the 0.15% cream formulation. It is important to note that the results mentioned in the NMAs were obtained through indirect comparisons, whereas our analysis provides a direct, head-to-head comparison of both therapies, which could be the cause of the contradiction in results. Additionally, our analysis showed high heterogeneity (Q = 15.2, P = 0.0005; I2 = 82%), prompting the use of a random-effects model. When applying a fixed-effects model, significant differences emerged between the two therapies in the PDX 0.5% subgroup (P = 0.002), with PDX 0.5% being superior to IMQ. The high heterogeneity was primarily due to the study by Nicolaidou, which used a stratification approach[30]. In this study, PDX 0.5% was applied only to lesions on keratinized sites, while the 0.15% cream was used for partially keratinized sites. It is well recognized that lesions on keratinized sites are more difficult to treat, which likely resulted in less effective treatment with IMQ[30]. As mentioned previously, neither therapy eradicates the underlying cause (i.e., HPV), making the recurrence of these lesions a significant concern in clinical practice. Previous research has indicated a lower recurrence rate for IMQ (6–26% after complete clearance) compared to PDX (6–100% at 8–12 weeks after complete clearance)[10,33]. The largest RCT conducted to date found a slightly higher recurrence rate for IMQ (31.7% vs. 26.6%) and a shorter median time to recurrence after complete clearance (122 days vs. 150 days) compared to PDX[27]. It is important to note that this trial not only compared IMQ and PDX but also evaluated the efficacy of the quadrivalent HPV vaccine (qHPV). For our analysis, we extracted data only from the arm that did not receive the qHPV vaccine to minimize confounding bias. In the vaccinated arm, the recurrence rate was slightly lower for IMQ (24% vs. 35%), and the median time to recurrence was significantly longer (149 days vs. 113 days) compared to PDX. This suggests that IMQ may offer benefits in preventing recurrence slightly more effectively in vaccinated individuals, making it a suitable choice in that context. The differing mechanisms of action of these drugs are reflected in their varying times to show a response to treatment. IMQ acts immunologically by stimulating the release of cytokines and interferon-alpha through the activation of TLR7 on macrophages[35]. In contrast, PDX causes direct cellular toxicity by inhibiting tubulin polymerization, which is essential for microtubule assembly[19]. Due to its immunological action, IMQ typically exhibits a delayed response time, necessitating a longer treatment course of around 16 weeks[10]. On the other hand, PDX’s direct cellular toxicity allows for a more rapid response time, typically requiring a treatment course of 4–5 weeks in most cases[10]. In the included RCT, comparable response times were observed between both groups in the non-vaccinated arm (114 days for IMQ vs. 117 days for PDX), whereas in the vaccinated arm, a slightly longer response time was required for IMQ compared to PDX (110 days vs. 84 days)[27]. The reason for the unexpectedly longer time required for clearance with PDX in the non-vaccinated arm remains unclear, as no significant error or bias was identified in the randomization process. Regarding safety, the overall risk of adverse events with IMQ was higher than with PDX, although this difference was not statistically significant (RR = 1.06, 95% CI: 0.76–1.53; P = 0.78). However, subgroup analysis based on adult and pediatric populations yielded different results. Adults had a significantly higher risk of adverse events from IMQ compared to PDX (RR = 1.22, 95% CI: 1.06–1.43; P = 0.02), while in children, the risk of adverse events was higher with PDX than with IMQ (RR = 0.51, 95% CI: 0.27–0.99; P = 0.05). The test for subgroup differences was also significant (P = 0.01). It is important to interpret these findings cautiously, as only one study reported adverse events in children[31]. This study had a very small sample size (n = 25), and the adverse events were self-reported by children and their guardians via a potentially unreliable questionnaire. This suggests that the findings could be an inaccurate depiction of actual statistics. Nonetheless, until future research provides more robust data, the study by Moresi et al[31] remains the only one reporting treatment outcomes for these drugs in children. Based on this data, it could be tentatively concluded that adults are more likely to experience adverse events from IMQ, while children are more likely to experience adverse events from PDX. The most common treatment-related adverse effects in both adults and children were erythema, inflammation, and edema, occurring less frequently in the IMQ group (6.5% vs. 7.1%)[28,31]. Skin erosions and ulcerations were also common in the IMQ group (11.0% vs. 7.1%)[27,28,31]. Although previous reports indicate fewer serious adverse events with IMQ compared to PDX, Gilson et al suggested otherwise, with anorectal infections, urticaria, and other serious adverse events being more common with IMQ[33]. The available data on direct comparisons between IMQ and PDX are scarce and contribute to the limitations of this review: (1) The studies presented have small sample sizes and inadequate power to draw reasonable conclusions; (2) one RCT directly comparing these two treatments, Gilson et al 2020, could not reach its planned sample size of 1000 patients due to financial issues, reporting data on only 500 patients; (3) the effect of HPV vaccines on treatment outcomes could not be analyzed, as only one study reported this, and we did not include these patients in our main analysis; (4) none of the studies reported data separately for HIV patients, so no conclusions can be drawn regarding this population; and (5) Gilson et al studied health-related quality of life (hrQOL) but only from an economic perspective[27]. The data provided did not indicate any significant difference between the two treatments, but given the trial design, these results cannot be applied to more practical clinical scenarios. Given these limitations, more large-scale studies, ideally RCTs, are needed to draw definitive conclusions. However, future RCTs comparing these two drugs may not occur, as they are expensive and resource-intensive. Both drugs are already extensively used in clinical practice, so there may be less incentive for pharmaceutical companies and regulatory bodies to fund such projects. However, observational studies can be conducted in settings such as hospitals and sexual health clinics, where a significant number of patients with CA present and receive treatment. We present some important points for future studies to address in the development of better clinical guidelines. Overall clinical efficacy for complete wart clearance appears to be similar for both PDX and IMQ, but longer treatment duration for PDX (> 4 weeks) can result in increased efficacy. Furthermore, there may not be a superior efficacy of PDX 0.5% solution compared to 0.15% cream; however, high heterogeneity in our data prevents definitive conclusions.The time to achieve complete wart clearance is longer for IMQ and shorter for PDX, but only in vaccinated individuals. In non-vaccinated individuals, it is similar. More studies comparing vaccinated and non-vaccinated populations are needed.IMQ may provide a very slight benefit against the recurrence of warts in vaccinated individuals, possibly due to its immunological mechanism, but further investigations are required.Children may be more likely to experience side effects with PDX, whereas adults may be more likely to experience them with IMQ. More studies on children are needed to confirm this. Overall clinical efficacy for complete wart clearance appears to be similar for both PDX and IMQ, but longer treatment duration for PDX (> 4 weeks) can result in increased efficacy. Furthermore, there may not be a superior efficacy of PDX 0.5% solution compared to 0.15% cream; however, high heterogeneity in our data prevents definitive conclusions. Overall clinical efficacy for complete wart clearance appears to be similar for both PDX and IMQ, but longer treatment duration for PDX (> 4 weeks) can result in increased efficacy. Furthermore, there may not be a superior efficacy of PDX 0.5% solution compared to 0.15% cream; however, high heterogeneity in our data prevents definitive conclusions. The time to achieve complete wart clearance is longer for IMQ and shorter for PDX, but only in vaccinated individuals. In non-vaccinated individuals, it is similar. More studies comparing vaccinated and non-vaccinated populations are needed. The time to achieve complete wart clearance is longer for IMQ and shorter for PDX, but only in vaccinated individuals. In non-vaccinated individuals, it is similar. More studies comparing vaccinated and non-vaccinated populations are needed. IMQ may provide a very slight benefit against the recurrence of warts in vaccinated individuals, possibly due to its immunological mechanism, but further investigations are required. IMQ may provide a very slight benefit against the recurrence of warts in vaccinated individuals, possibly due to its immunological mechanism, but further investigations are required. Children may be more likely to experience side effects with PDX, whereas adults may be more likely to experience them with IMQ. More studies on children are needed to confirm this. Children may be more likely to experience side effects with PDX, whereas adults may be more likely to experience them with IMQ. More studies on children are needed to confirm this. Conclusion The clinical effectiveness of IMQ is comparable to that of PDX but has comparatively more adverse effects in adults and fewer in children. However, the pediatric findings have a high risk of being unreliable due to the limited sample size (n = 25). Furthermore, the studies compiled in the systematic review showed that IMQ generally has a comparable time to complete clearance but a shorter time to wart recurrence compared to PDX, as well as a higher overall rate of wart recurrence. Still, IMQ seems to be slower in achieving complete clearance but better in preventing wart recurrence in vaccinated individuals, probably owing to its immunological mechanism of action. This might suggest a slight superiority of IMQ over PDX in vaccinated individuals, as well as in the pediatric population, a finding that needs further research to be fully substantiated.